CureMatch
×
  • Physicians
    • Patients
  • About Us
  • News
    • CureMatch News
    • Validation and Research
    • Events & Conferences
  • Contact

CureMatch Precision Medicine Leaders Featured at Summit: Stephane Richard and Jessica Federer at PMLS2018

CureMatch Precision Medicine Leaders Featured at Summit: Stephane Richard and Jessica Federer at PMLS2018
Events

Jessica Federer Joins Advisory Board to Advance Cancer Cures. Stephane Richard and Jessica Federer to speak at PMLS2018.

SAN DIEGO, CA – June 26, 2018 – CureMatch, Inc., a digital precision oncology company bridging the gap between legacy cancer treatments and advances in personalized medicine, announces the addition of Jessica Federer to its advisory board. Ms. Federer along with CureMatch CEO, Stephane Richard, Ph.D., are featured at the 3rd annual Precision Medicine Leaders Summit (PMLS) in Jersey City, June 26-28.

Jessica Federer was the Chief Digital Officer and worldwide head of Digital Development at Bayer, a global life sciences leader. While at Bayer, she held positions in Global Regulatory Affairs, Market Access, Communications and Public Affairs. Ms. Federer is adept at translating digital developments into meaningful advancements for business and society and is recognized as one of the top 100 global CDOs, a “Power-Lady” of the German economy, and a leading Health Tech Influencer.

jessica-federer-curematch-advisor“Health is holistic, but traditional healthcare silos information and treatment. Eradicating diseases like cancer requires the development of disruptive technologies to bridge these silos in real and meaningful ways,” stated Jessica Federer, CureMatch Advisor.

“The CureMatch approach is transformative, simultaneously advancing science while also addressing care disparities. It’s opening the door for everyone to get the best oncology care possible.”

Ms. Federer is featured at PMLS, moderating ‘Predictive Analytics in Precision Medicine – Harnessing the power of RWE, NGS and Liquid Biopsies to Inform and Help Refine Patient Selection Algorithms’ on Tuesday, June 26 at 4:35. The panel will explore the data revolution in medicine and highlight evolving technologies that support diagnostic development and data generation. Next-Generation Sequencing (NGS) and Liquid Biopsies provide robust biomarkers which coupled with new data insights offer predictive analytics that focus on patient selection/monitoring.

PMLS2018-Stephane-Richard

CureMatch CEO, Stephane Richard, poses the question, “How can the best possible cancer treatments be identified with such a huge amount of complicated data and knowledge to process?”  To discuss solutions, Dr. Richard leads the roundtable, ‘The Use of Precision Oncology Decision Support Systems in the Clinical Practice’ at PMLS on Tuesday, June 26 at 5:30pm.

“The vast majority (>85%) of cancer patients are treated in local communities. Most oncologists do not have direct access to the top academic centers conducting cutting-edge research. This creates gaps in quality-of-care,” states Stephane Richard, Ph.D., CEO of CureMatch. “Precision medicine powered by artificial intelligence (AI) offers community oncologists access to the best studies, the latest clinical results, and the top ranked combination therapies, all optimized for each individual patient based on molecular profile.”

CureMatch offers oncologists around the world therapeutic cancer treatment decision support. The PreciGENE® AI technology offers ranked predictions that correlate with exceptional responses.

###

About Precision Medicine Leaders Summit
The Precision Medicine Leaders’ Summit has firmly established itself as the definitive thought leadership event within this burgeoning sphere. After two successful years in San Diego, we are bringing the conference to the friendly confines of Jersey City. With close proximity to numerous biopharma companies, academic institutions, leading medical centers, and Wall Street, the 2018 event promises to engage a diverse group of participants.

About CureMatch®
CureMatch, Inc. is a digital precision oncology company bridging the gap between legacy cancer treatments and advances in personalized medicine. Utilizing proprietary algorithms to analyze over 4.5 million combinations of commonly used as well as newly approved cancer treatments found in massive pharmacological and clinical databases,  CureMatch scores and ranks Personalized Combination Therapy® options to target specific molecular aberrations and improve the precision of cancer treatment recommendations. This actionable intelligence guides oncologists to effectively customize treatment for each individual patient. Based in San Diego, CA, the CureMatch technology has expert foundation in supercomputing, oncology, genetics, molecular and cell biology. For more information, visit https://www.curematch.com

Media Contact
Name: Larissa Anderson
Company: CureMatch
Phone: 858-859-2873
Email: press@curematch.com

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • CureMatch Appoints Visionary Leader, Ally Perlina, as Chief Science Officer

    Leader brings two decades of industry experience in precision medicine, pharmaceutical and translational science to...

  • Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials

    Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer....

  • Servier and CureMatch® Launch Their Self-Certified CE-Marked Clinical Decision Support Software, Bionov™

    PARIS and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ — WeHealth™ Digital Medicine, Servier Group’s e-health business unit, and CureMatch®, a...

  • How Precision Medicine Can Help You

    Precision medicine is revolutionizing cancer care. Dr. Razelle Kurzrock highlights how personalized treatments improve patient...

  • 64 FDA-Approved Drugs Identified as Potential Treatments for COVID-19

    Scientists from CureMatch and UCSD use pharmacophore-based drug design and a molecular docking technique to...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription drugs in the...

Validation

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

  • CureMatch at WIN Symposium 2018 Winning the War against Cancer with Precision Oncology

    SAN DIEGO, CA – June 22, 2018 – CureMatch, Inc. offers results...

  • Personalized Drug Combinations Can Lead to Better Results for Cancer Patients

    A featured article in The Scientist magazine highlights CureMatch co-founder Dr. Razelle...

Archives

  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (619) 277-4761

FAX: +1 (858) 430-5813

Quick Links

  • Physicians
  • About CureMatch
  • News and Latest Posts
    • CureMatch News
    • Validation and Case Studies
    • Events and Conferences
  • Contact Us
  • FAQ

Latest News and Results

  • CureMatch Appoints Visionary Leader, Ally Perlina, as Chief Science Officer Dec 15

    Leader brings two decades of industry experience in precision medicine, pharmaceutical and translational science to...

  • Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials Dec 13

    Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy Oct 19

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer....

© 2021 CureMatch, Inc. CureMatch is a registered trademark.
FAQ | Terms of Use | Privacy Policy | HIPAA Notice

We’d like to send you a CureMatch Sample Analysis

 

Sample Analysis Download Form

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data